When providers document Prescription Drug Management in an evaluation and management (E/M) service, the assumption is often that a prescription refill counts as “risk.” The reality is more complicated. Medicare Administrative Contractors (MACs) each define it differently, and that can affect coding and compliance.

CGS (Kentucky, Ohio): The Toughest
Continuing a stable medication without change does not qualify. “Stable hypertension; continue lisinopril” earns no credit here.

First Coast (Florida, Puerto Rico, U.S. Virgin Islands): Flexible but Detailed
Initiating, adjusting, discontinuing, or even continuing a drug counts—but only if the documentation includes the name, dose, decision, and rationale tied to the condition.

NGS (Northeast, Midwest): Must Show the “Why”
Listing medications or writing “renewed” does not qualify. Providers must explain why a drug is continued, adjusted, or discontinued and connect it to patient risks or benefits.

Noridian (Western States & Territories): Risk Matters
Credit depends on evaluating risks—interactions, bleeding, or complications. Even documenting patient education or caregiver monitoring can support Prescription Drug Management.

Novitas (South, Mid-Atlantic): Reasoning Required
Continuation is fine, but the record must show medical necessity. Refills without tying the drug to a problem addressed won’t count.

AMA (National View)
The American Medical Association (AMA) reminds providers: simply reviewing a list isn’t enough. Documentation must connect the drug to the patient’s condition and risk profile.

Quick Takeaways

  • “Refill” or “medication list reviewed” ≠ Prescription Drug Management.
  • CGS is strictest—stable therapy doesn’t count.
  • First Coast & Novitas allow continuation with rationale.
  • NGS & Noridian demand detailed reasoning and risk evaluation.
  • AMA: Always connect medication decisions to the patient’s clinical situation.

Bottom line: To get credit, don’t just write what medication is prescribed—show why it matters for this patient at this visit.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Share This